Upload
lukeph
View
235
Download
0
Embed Size (px)
Citation preview
7/30/2019 Novartis Company PDF
1/14
| SEO Presentation | 4 January 20111
Our focus is on patients
Our purpose is to care and cure.We provide medicines to treat and prevent diseases,
ease suffering and improve quality of life.
7/30/2019 Novartis Company PDF
2/14
| SEO Presentation | 4 January 20112
Novartis is a world-leading healthcare company
Leading market position
One of 20 largest companies by market capitalization
Among most respected companies globally
2009 USD billion
Net sales: 44.3
Net income: 8.5
R&D investment: 7.5
Canada and LATAM
US
EuropeAsia/Africa/Australasia
Sales by region 2009Key figures
7/30/2019 Novartis Company PDF
3/14
3
The healthcare environment is undergoingunprecedented change
Agingpopulation
Unhealthylifestyles
Emergingmarkets
Advances inscience andtechnology
Poor nutritional habits and sedentary
lifestyles are increasing the prevalenceof chronic diseases
Economic growth of emerging countriesis providing healthcare access
New technological discoveries andtrends are enabling the development ofinnovative medicines while increasingthe cost of innovation
7KHZRUOGVSRSXODWLRQLVDJLQJ0RUHhealthcare treatments are needed, alsoprompting payors to aggressivelymanage costs
| SEO Presentation | 4 January 2011
7/30/2019 Novartis Company PDF
4/14
4
Environment Patient needs Novartis portfolio
Pharmaceuticals
Vaccines and
Diagnostics
Sandoz(Generics)
Consumer Health(OTC, Animal Health
and CIBA Vision)
Full rangeof healthcareoptions
Innovativemedicines
Prevention
Affordableoptions
Self-care
We believe our portfolio best meets the varied andoften complex needs of patients and societies
| SEO Presentation | 4 January 2011
7/30/2019 Novartis Company PDF
5/14
5
We have a broad healthcare portfolio
PharmaceuticalsInnovative patent-protectedmedicines
Vaccines andDiagnostics
Vaccines and diagnostic toolsto protect against life-threatening diseases
SandozAffordable, high-quality genericmedicines and biosimilars
ConsumerHealth
Strong, trustworthy brands forknowledgeable consumersOTC (Over-the-Counter) Animal HealthCIBA Vision
2009 net sales by division
Sandoz
Pharmaceuticals
V&D
ConsumerHealth
| SEO Presentation | 4 January 2011
7/30/2019 Novartis Company PDF
6/14
6
Strengthening the healthcare portfolio with Alcon
Eye care segment is highly attractive Large and profitable segment (USD 25 bn, 20%-30% EBIT)
Dynamic growth (aging population, emerging markets, innovation)
Alcon is the world leader in this attractive segment
Clear No. 1 in surgical and pharmaceutical eye care markets Strong performance track with double digit top- and bottom-line
Alcon stake expected to strengthen Novartis growth portfolio
Access to one of the fastest growing healthcare areas
Strengthen non-branded Rx businesses and expand in specialty areas Synergies of portfolios (front vs. back-of-the-eye), manufacturing and
distribution
Diversify risk (fewer generics, more self-pay)
| SEO Presentation | 4 January 2011
7/30/2019 Novartis Company PDF
7/14
7
We seek to constantly innovate
Unrivaled pipeline with approximately 152 projects inclinical development
Most new US drug approvals in the industry since 2000
2QHRIWKHLQGXVWU\VELJJHVWLQYHVWRUVLQUHVHDUFK
More than 17% of annual group net salesreinvested in R&D in 2008
Innovation across the Novartis group
Focusing on unmet medical needs inspires us toconnect science with customer insights to developnew products and drive industry standards
| SEO Presentation | 4 January 2011
http://creative.gettyimages.com/source/Search/88','28','1','http://creative.gettyimages.com/source/Search/66','6','1','SS187/30/2019 Novartis Company PDF
8/14
8
Novartis A leading healthcare company
1996 1997 1999 2000 2001 2002 2003 2005 2006 2007 2008
March:Sandoz andCiba-Geigyannouncemerger plans
December:Formation ofNovartis
May:ADS listingon New YorkStockExchange
July:Novartisone of firstcompaniesto signUN GlobalCompact
May:Initial stakeacquired inRoche, laterincreasingto 33%
November:NITD opensinSingaporeto researchtropicaldiseases
May:Creationof NovartisInstitutes forBiomedicalResearch forpharma-ceuticalsresearch
August:Acquisitionof Lek, aSloveniangenericscompany
May:Unificationof allgenericsoperationsunderhistoricSandozbrand
June/July:Acquisitionof genericleadersHexal andEon Labs
August:Acquisitionof OTCbrands fromBristol-MeyersSquibb
April:Entry intohumanvaccinesthrough Chironacquisition
February:Opening ofNovartisVaccines Institutefor Global Health
April/July:Rights to acquiremajority stake inAlcon, a worldleader in eyecare, from Nestl,initial 25% stakepurchased in July
March:Spin-offof CibaSpecialtyChemicalsbusiness
December:Spin-off ofagribusinessto formSyngenta
February:Sale ofNutrition& Santbusiness
July:Sale of MedicalNutritionbusiness
September:Sale of Gerberbaby productsbusiness
Healthcare Other
| SEO Presentation | 4 January 2011
7/30/2019 Novartis Company PDF
9/14
9
Focused diversification in healthcare
20021996 2007
45%80% 100%
Healthcare Other
2009 targeted acquisitions and strategic investments:
EBEWE Pharmaspecialty generics
85% stake inZhejiang Tianyuan
| SEO Presentation | 4 January 2011
7/30/2019 Novartis Company PDF
10/14
10
Strong performance in all business areas
Sales by division 2009 Sales by region 2009Consumer
Health
Sandoz
Pharmaceuticals
Company overviewEmployees: 99 834
Countries: 140
Headquarters: Basel, Switzerland
2009 USD billion
Net sales: 44.3
Net income: 8.5
R&D investment: 7.5
Key facts
V&D
Canada and LATAM
US
EuropeAsia/Africa/Australasia
| SEO Presentation | 4 January 2011
7/30/2019 Novartis Company PDF
11/14
11
Gilenya
| SEO Presentation | 4 January 2011
7/30/2019 Novartis Company PDF
12/14
12
Operating responsibly is integral to our success
Corporate citizenship at Novartis rests on four pillars: patients,people and communities, the environment and business conduct
Environment
Risk prevention& management
Resourcemanagement
Patients
Access
Research
Clinical trials Dialogue
People andcommunities Diversity &
inclusion
Living wage
Health & safety
Communityinvolvement
Emergency aid
Businessconduct Integrity &
Compliance
Marketingpractices
Third-partymanagement
Integrity Line
| SEO Presentation | 4 January 2011
7/30/2019 Novartis Company PDF
13/14
13
Access-to-medicine programs in 2009 we supported 79.5 million patients
1Novartis Institute for Tropical Diseases;2Novartis Vaccines Institute for Global Health;3Based on approximate market value
2009
Programs andresearch valuedat USD 1.5 bn3
Contributed 3%
of net sales
Coartem subsidized84 million treatments shipped cumulativelydelivered 300 million treatments, helping to saveabout 750,000 lives
Leprosy medication free of charge>4.5 million patients cured since 2000
Tuberculosis medicine donations500,000 treatments committed, 50% delivered
Glivec patient assistanceFree to >37,000 patients in about 80 countries
NITD1 in SingaporeFocus on tuberculosis, dengue fever and malaria
NVGH2 in Siena, ItalyVaccines research institute for neglected diseases
| SEO Presentation | 4 January 2011
7/30/2019 Novartis Company PDF
14/14
14
We make a difference for patients
0\GLVHDVHDIIHFWVVRIHZpeople, no one cared toUHVHDUFKDWUHDWPHQWXQWLOQRZ
Siobhan Walshrare disease patient
7KHPRUH,WDNHFDUHRImyself, the less othersZLOOKDYHWR
Odell Hallavid exerciser
,IWKHUHZDVDYDFFLQHIRUmeningitis B, my daughterZRXOGVWLOOEHDOLYHWRGD\
Robert Lelandfather
:KHQ\RXWDNHDVPDQ\medicines as I need,FRVWLVDQLVVXH
Luz Martinezsenior citizen
Novartis is deploying our understanding of
biological mechanisms toward a range ofmajor diseases while also offering hope topatients with rare illnesses who couldbenefit from these discoveries.
Novartis empowers patients and consumersby providing a wide range of readily-availablehealthcare products.
Novartis is a leader in providing vaccines that
protect against life-threatening viral andbacterial diseases, with a priority researchfocus on developing new vaccines to preventmeningococcal infections.
Novartis offers patients high-quality,affordable generic medicines to reducefinancial burden.
| SEO Presentation | 4 January 2011